Larimar Therapeutics Announces Positive Topline Phase 1 Clinical Trial Data of CTI-1601 in Friedreich ataxia patients.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for Friedreich ataxia and other complex rare diseases, announced today topline data from its Phase 1 ...
FDA Grants Orphan Drug Designation to HM15211 for Idiopathic pulmonary fibrosis (IPF)
Hanmi Pharmaceutical's LAPS Triple Agonist (HM15211) has been designated an orphan drug to treat Idiopathic pulmonary fibrosis (IPF). Pulmonary fibrosis affects the interstitium, the lung tissue that ...